MEKK2 mediates aberrant ERK activation in neurofibromatosis type I

MEKK2 mediates aberrant ERK activation in neurofibromatosis type I

Neurofibromatosis type I (NF1) is characterized by prominent skeletal abnormalities mediated in part by aberrant ERK pathway activation due to NF1 loss-of-function. Here, the authors report the MEKK2 is a key mediator of this aberrant ERK activation and that MEKK2 inhibitors, including ponatinib, am...

Full description

Bibliographic Details
Main Authors: Seoyeon Bok, Dong Yeon Shin, Alisha R. Yallowitz, Mark Eiseman, Michelle Cung, Ren Xu, Na Li, Jun Sun, Alfred L. Williams, John E. Scott, Bing Su, Jae-Hyuck Shim, Matthew B. Greenblatt
Format: Article
Language:English
Published: Nature Publishing Group 2020-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-020-19555-6

Internet

https://doi.org/10.1038/s41467-020-19555-6

Similar Items